Prof. Angelika Amon, winner of a 2019 Breakthrough Prize, speaks with Nature about her reaction to winning the prize and her research investigating the consequences of a cell having the wrong number of chromosomes. Amon explains that that next big challenge for her work is to “figure out how these changes in copy number affect cancer.”
Prof. Angelika Amon is honored as one of the recipients of this year’s Breakthrough Prize for her work determining “how extra or missing chromosomes in a person’s genetic makeup can lead to disease,” reports Olivia Vanni for the Boston Herald.
National Geographic reporter Nadia Drake highlights the work of Prof. Angelika Amon, winner of the 2019 Breakthrough Prize in Life Sciences. “I’m extremely grateful to have been selected,” says Amon. “I’m the representative of all the people who work with me over the years, who this prize is really for—my students and postdocs and trainees, really, they are the winners here.”
Writing for The Boston Globe, Prof. Eric Lander, president of the Broad Institute, argues for enabling cancer patients to become actively involved in cancer research. “Patients must have an active voice in decisions. Patient data should never be sold,” Lander writes. “Researchers anywhere should have rapid access to the de-identified clinical and genomic data, to ensure that anyone can make discoveries.”
Prof. Angelika Amon received this year’s Breakthrough Prize in Life Sciences for her “contributions to finding significant solutions to curing human diseases,” while Profs. Chenyang Xu, Daniel Harlow, Matt Evans and research scientist Lisa Barsotti received New Horizons Prizes for “early-career achievements in their respective fields,” reports Xinhua.
Prof. Angelika Amon is a recipient of this year’s Breakthrough Prize “for her work on aneuploidy, irregularities in the number of chromosomes,” which could lead to a new understanding of cancer, writes Martin Finucane for The Boston Globe. Prof. Chenyang Xu, Prof. Matt Evans and research scientist Lisa Barsotti received New Horizons Prizes in physics, while Prof. Daniel Harlow received one in math.
BBC Click spotlights a new semi-autonomous, wearable robot developed by MIT researchers that takes different types of measurements from the skin to identify conditions such as skin cancer. “The doctor can see your whole body, but the doctor doesn’t pick up the small changes in your skin conditions, which the robot can do,” says graduate student Artem Dementyev.
Boston Herald reporter Alexi Cohan highlights a new lab at MIT, led by Prof. Tyler Jacks, that will investigate how the immune system can be used to treat and manage pancreatic cancer. “In the long term we hope that the work that we are doing will help us diagnose the disease at even early stage and maybe even prevent it altogether,” Jacks explains.
MIT researchers have developed a machine learning system that could reduce the number of chemotherapy and radiotherapy treatments that glioblastoma patients receive, reports the Xinhua News Agency. The system “finds an optimal treatment plan, with the lowest possible potency and frequency of doses that should still reduce tumor sizes,” Xinhua explains.
MIT researchers have developed a sensor that can determine if cancer cells are responding to a certain chemotherapy drug. “Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient's tumor,” writes Li Xia for Xinhua.
New Scientist reporter Chelsea Whyte spotlights Prof. Regina Barzilay’s quest to revolutionize cancer treatment by applying AI techniques in ways that could help doctors detect cancer earlier. Barzilay explains that she is committed to, "applying the best technologies available to what we care about the most – our health.”
MIT researchers found that the effectiveness of the chemotherapy drug methotrexate increases when supplemented with a common dietary amino acid, writes Victoria Forster of Forbes. Prof. David Sabatini, a co-author on the study, “is hopeful about the prospects for supplementation improving the therapy in the future,” says Forster.
By using “nanoparticle ‘backpacks’ with immune-stimulating drugs,” MIT researchers were able to enhance T cells and destroy solid tumors without harmful side effects, reports Allen Cone of UPI. "We found you could greatly improve the efficacy of the T cell therapy with backpacked drugs that help the donor T cells survive and function more effectively,"explains Prof. Darrell Irvine.
STAT reporter Justin Chen writes about a new study that examines why patients with pancreatic cancer often experience significant weight loss. Prof. Matt Vander Heiden explains that the findings show, “pancreatic cancer patients clearly have a lot of tissue wasting and whether it’s good or bad, we can now say that it’s not necessarily bad at diagnosis.”
A new paper co-authored by Prof. Omer Yilmaz and Prof. David Sabatini found that fasting substantially “improves stem cells' ability to regenerate,” reports Xinhua. The researchers hope this finding could lead to new drug treatments that “stimulate regeneration without requiring patients to fast, which is difficult for most people.”